| Columbia
MDR Phase1Clinical Trial |
|
|
|
|
|
|
|
|
|
|
| l | Safety
demonstrated: no delayed engraftment or |
||||||||
| RCR |
|||||||||
| l | Feasibility
shown: Large scale retroviral |
||||||||
| supernatants
and CD34+ cells used in scale-up |
|||||||||
| l | Pre-infusion:
High-level CD34+ transduction in |
||||||||
| BFU-E
and CFU-GM |
|||||||||
| l | Post-infusion:
2/5 patients with low level MDR |
||||||||
| PCR
+ cells |
|||||||||